The Federal Circuit has denied Amgen’s Emergency motion for a temporary injunction pending en banc consideration and review in Amgen v. Sandoz. Per the Federal Circuit’s July 21st decision, Sandoz was enjoined from marketing its biosimilar filgrastim product, Zarxio, until 180 days from the date it received FDA approval for its product. That original injunction ends today, September 2.
For coverage of Amgen’s emergency motion for a temporary injunction and Sandoz’s opposition, see our previous posts here and here. For more background on the Amgen v. Sandoz appeal, including analysis of the considerations at play in a possible en banc review, see our August 12th webinar, available here.